MEA Acute Myeloid Leukemia Diagnostics Market - Industry Trends and Forecast to 2034
Middle East and Africa Acute Myeloid Leukemia Diagnostics Market is projected to register a substantial CAGR of 7.9% in the forecast period of 2024 to 2031. The new market report contains data for the historic year 2022, the base year of calculation is 2023, and the forecast period is 2024 to 2031.
Market SegmentationMiddle East and Africa Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments, and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), MONOCYTIC (M5), Erythroleukemia (M6) and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Driver• Increasing diagnostic products for leukemia cancer
Restrain• Late diagnosis and Poor prognosis of leukemia
Opportunity• Initiatives by government and other authorities for life sciences and funding
Market PlayersSome of the major market players in Middle East and Africa acute myeloid leukemia diagnostics market are: • F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific, Inc.
• QIAGEN
• Abbott
• Siemens Healthcare GmbH
• Hologic, Inc.
• Agilent Technologies, Inc.
• DiaSorin S.p.A.
• Illumina, Inc.
• BIOMÉRIEUX
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.